GATC Biotech has signed a commercial agreement with Molecular Health to market and support Molecular Health’s state-of-the-art system for tumour profiling. Under this agreement, GATC Biotech will make the company’s analytical software, TreatmentMAP, available to patients worldwide.
Every cancer is unique, which is why cancer patients respond differently to cancer treatments. Scientific discoveries and technological breakthroughs can provide oncologists with more in-depth information about individual tumour biology, helping to identify potentially beneficial therapeutic agents based on the molecular makeup of the individual tumour. Based on the patient’s molecular and clinical data, the extensive biomedical data warehouse of Molecular Health and the TreatmentMAP analytical software provide physicians with detailed, actionable information. This way, it will be possible to select the best suitable treatment to an individual tumour profile. TreatmentMAP is the first registered medical device of its kind in Europe for personalized cancer medicine. In the United States, it is run as an end-to-end laboratory test that includes next-generation sequencing (NGS).
Lutz Voelker, Chief Executive of Molecular Health, commented: “TreatmentMAP is a powerful tool designed to support the decision making of oncologists, hence improving the potential prospect of treating cancer and improving the life of cancer patients. This sales and marketing agreement with GATC Biotech has significantly enhanced our prospects of exploiting TreatmentMAP’s definitive market potential throughout.“
Molecular Health has launched the product in the US and Germany and will now work with GATC Biotech to address the rapidly growing interest in the market. This agreement provides Molecular Health with a powerful commercial and scientific partner in this important market. This relationship will contribute substantially to both companies’ growth.
Molecular Health was part of our South Germany Tour. Here is the interview with Stephan Brock, CEO of the company:
Let's Continue The Conversation
Feel free to send us comments about this article to email@example.com and/or comment on that article on social media.